Analysts at Guggenheim initiated coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research report issued to clients and investors on Tuesday, MarketBeat reports. The brokerage set a “neutral” rating and a $16.00 price target on the stock. Guggenheim’s price objective would indicate a potential downside of 14.02% from the stock’s current price.
Other equities research analysts also recently issued research reports about the stock. BidaskClub downgraded shares of Teva Pharmaceutical Industries from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 16th. Citigroup downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and lowered their target price for the company from $32.00 to $19.00 in a research note on Wednesday, August 16th. Cantor Fitzgerald set a $17.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Monday, September 11th. Royal Bank of Canada upped their price target on shares of Teva Pharmaceutical Industries from $8.00 to $13.00 and gave the company an “underperform” rating in a report on Sunday, November 5th. Finally, Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Monday, September 11th. Five research analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $20.65.
Shares of Teva Pharmaceutical Industries (NYSE TEVA) traded up $1.31 during trading hours on Tuesday, reaching $18.61. 66,141,613 shares of the company’s stock traded hands, compared to its average volume of 26,438,098. Teva Pharmaceutical Industries has a 1 year low of $10.85 and a 1 year high of $38.31. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. The company has a market capitalization of $18,907.76, a P/E ratio of 4.30 and a beta of 0.55.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
